The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

Hepatology

Volumn 43, Issue 4, 2006, Pages 761-770

  Paeshuyse, Jan ^a   Kaul, Artur ^b   De Clercq, Erik ^a   Rosenwirth, Brigitte ^d   Dumont, Jean Maurice ^c   Scalfaro, Pietro ^c   Bartenschlager, Ralf ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DEBIOPHARM SA   (Switzerland)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DEBIO 025; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; HEPACIVIRUS; HEPATITIS C; HUMANS; OSMOLAR CONCENTRATION; RNA, VIRAL; VIRUS REPLICATION;

EID: 33646015668     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21102     Document Type: Article

References (46)

1. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004;63:71-180.
2. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003;13:57-68.
3. Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003;23(Suppl 1):35-46.
4. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001;61:1957-2016.
5. Hatziioannou T, Perez-Caballero D, Cowan S, Bieniasz PD. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol 2005;79:176-183.
6. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004;78:12800-12808.
7. Caffrey CR, Gsell C, Ruppel A. Schistosoma japonicum is less sensitive to cyclosporin A in vivo than Schistosoma mansoni. J Parasitol 1999;85:736-739.
8. Millership JJ, Chappell LH, Fallon PG. Synergistic action of cyclosporin A and polyspecific rabbit anti-sera against murine Schistosoma mansoni. Parasite Immunol 1996;18:71-77.
9. Munro GH, Brannan LR, Chappell LH, Thomson AW, McLaren DJ. The larvicidal activity of cyclosporin A against Schistosoma mansoni in mice. Parasitology 1991;102(Pt 1):57-63.
10. Dunn MA. Suppressive effects of cyclosporin A in murine schistosomiasis. HEPATOLOGY 1989;9:339-340.
11. Bout DT, Deslee D, Capron AR. Protection against schistosomiasis produced by cyclosporin A. Am J Trop Med Hyg 1984;33:185-186.
12. Bueding E, Hawkins J, Cha YN. Antischistosomal effects of cyclosporin A. Agents Actions 1981;11:380-383.
13. Bell A, Wernli B, Franklin RM. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin. Biochem Pharmacol 1994;48:495-503.
14. Uadia PO, Ezeamuzie IC, Ladan MJ, Gerrets R. Antimalarial activity of cyclosporins A, C and D. Afr J Med Med Sci 1994;23:47-51.
15. Biswas S, Saxena QB, Upender M. Antimalarial effect of cyclosporin-A on murine P. berghei and human P. falciparum. Indian J Malariol 1991;28: 1-8.
16. Kocken CH, van der WA, Rosenwirth B, Thomas AW. Plasmodium vivax: in vitro antiparasitic effect of cyclosporins. Exp Parasitol 1996;84:439-443.
17. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42-47.
18. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. HEPATOLOGY 2003;38:1282-1288.
19. Teraoka S, Mishiro S, Ebihara K, Sanaka T, Yamaguchi Y, Nakajima I, et al. Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus. Transplant Proc 1988;20(Suppl 3):868-876.
20. Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ, Jensen DM. A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol 2003;36:352-355.
21. Inoue K, Yoshiba M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc 2005;37:1233-1234.
22. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-572.
23. Hubler F, Rückle T, Patiny L, Muamba T, Guichou JF, Mutter M, et al. Synthetic routes to NEtXaa4-cyclosporin A derivates as potential anti-HIV I drugs. Tetrahedron Letters 2000;41:7193-7196.
24. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 2003;278:11979-11984.
25. Hashimoto H. Fused Cyclic Compounds and Medicinal Use Thereof. Patent WO2003000254 A1.
26. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280:36784-36791.
27. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279:17508-17514.
28. Summa V. VX-950 (Vertex/Mitsubishi). Curr Opin Invest Drugs 2005; 6:831-837.
29. Vtolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, Schalm SW, et al. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 2003;110:201-209.
30. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75:1437-1449.
31. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002;76: 13001-13014.
32. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
33. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
34. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
35. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001;75: 4614-4624.
36. Prichard MN, Shipman C, Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990;14:181-205.
37. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9299.
38. Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, et al. Naturally occurring capsid substitutions render HIV-1 cyclophilin a independent in human cells and trim-cyclophilin resistant in owl monkey cells. J Biol Chem 2005.
39. Mlynar E, Bevec D, Billich A, Rosenwirth B, Steinkasserer A. The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. J Gen Virol 1997;78:825-835.
40. Dorfman T, Gottlinger HG. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. J Virol 1996;70:5751-5757.
41. Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V, et al. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J Virol 1995;69:2451-2461.
42. Steinkasserer A, Harrison R, Billich A, Hammerschmid F, Werner G, Wolff B, et al. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J Virol 1995;69:814-824.
43. Rosenwirth B, Billich A, Datema R, Donatsch P, Hammerschmid F, Harrison R, et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother 1994;38:1763-1772.
44. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005;129: 1031-1041.
45. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-122.
46. Steyn D, Richman DD, Aeschlimann C, Dumont JM, Grosgurin P, Rosenwirth B, et al. A double blind placebo controlled study in HIV-1-Infected Subjects on the Safety, Pharmacokinetics and Antiviral Effect of Cyclophilin a Targeting Debio-025, 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver, Colorado, February 2006.